ADC Therapeutics announced closure of its UK R&D site, layoffs cutting 30% of staff, and discontinuation of several preclinical oncology programs following clinical failures. The restructuring aims to concentrate resources on approved and prioritized candidates but highlights the challenges the company faces amid pipeline setbacks.